MIR206

Summary

MIR206 (microRNA 206, HGNC:31584) is a microRNA gene on chromosome 6p12.2.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. Disruption of the encoded miRNA has been implicated in multiple skeletal muscle disorders, including amyotrophic lateral sclerosis (ALS) and Duchenne muscular dystrophy (DMD), as well as in several cancers. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 406989 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:31584
Approved symbol	MIR206
Name	microRNA 206
Location	6p12.2
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-206
Ensembl gene	ENSG00000207604
Ensembl biotype	miRNA
OMIM	611599
Entrez	406989
RNAcentral	URS0000389B41 — miRNA, 86 nt, 21 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000384872

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000384872 — 1 exons

Exon	Start	End
ENSE00001499879	52144349	52144434

Expression profiles

Bgee: expression breadth broad, 23 present calls, max score 96.08.

Top tissues by expression

23 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
colon	UBERON:0001155	96.08	gold quality
adrenal tissue	UBERON:0018303	80.88	gold quality
monocyte	CL:0000576	80.48	gold quality
muscle of leg	UBERON:0001383	78.12	gold quality
blood	UBERON:0000178	77.11	gold quality
gastrocnemius	UBERON:0001388	72.97	gold quality
heart left ventricle	UBERON:0002084	71.20	gold quality
stomach	UBERON:0000945	69.90	gold quality
tonsil	UBERON:0002372	68.60	gold quality
right atrium auricular region	UBERON:0006631	67.73	gold quality
ascending aorta	UBERON:0001496	66.03	gold quality
omental fat pad	UBERON:0010414	65.52	gold quality
esophagus mucosa	UBERON:0002469	64.57	gold quality
skin of leg	UBERON:0001511	63.80	gold quality
endocervix	UBERON:0000458	63.59	gold quality
uterus	UBERON:0000995	63.58	gold quality
tibial nerve	UBERON:0001323	62.26	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	61.97	gold quality
prostate gland	UBERON:0002367	61.86	gold quality
thoracic mammary gland	UBERON:0005200	61.22	gold quality
thyroid gland	UBERON:0002046	53.91	silver quality
corpus callosum	UBERON:0002336	45.49	silver quality
left testis	UBERON:0004533	42.72	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.65

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): AP1, ESR1, ESRRG, FOS, FOXC1, JUN, MYOD1, NR0B2, SRF, YY1

Literature-anchored findings (GeneRIF, showing 40)

• miR-206 could be a novel candidate for endocrine therapy that targets only ERalpha in breast cancer. (PMID:18593897)
• miR-206 contributes to EGFR-mediated abrogation of estrogenic responses in MCF-7 cells, contributes to a Luminal-A- to Basal-like phenotypic switch, and may be a measure of EGFR response within Basal-like breast tumors (PMID:19423651)
• The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation. (PMID:19620785)
• miR-18a, miR-18b, miR-193b, miR-206 and miR-302c, were confirmed to directly target ERalpha in 3’-untranslated region reporter assays. (PMID:19684618)
• miR-1/206 suppressed c-Met expression in rhabdomyosarcoma and could function as a potent tumor suppressor in c-Met-overexpressing tumors. (PMID:19710019)
• MicroRNA-206 targets notch3, activates apoptosis, and inhibits tumor cell migration and focus formation. (PMID:19723635)
• Studies indicate that loss of tumor suppressor miR-206, and the overexpression of oncogenic miR-21 have been observed in many breast cancers. (PMID:20346098)
• miR-206 showed an over-expression in 5 of 7 myotonic dystrophy type 1 patients (threshold = 2, fold change between 1.20 and 13.22, average = 5.37) compared to the control group. (PMID:20487562)
• increased expression of miRNA-206 modulating histone acetylation is associated with Waldenstrom macroglobulinemia. (PMID:20519629)
• These results raise the possibility of using circulating muscle-specific miRNAs, especially miR-206, as landmark biomarkers for rhabdomyosarcoma. (PMID:20696132)
• Overexpression of microRNA-206 inhibits cell migration and invasion of lung cancer cells. (PMID:21157919)
• Results identify a KLF4-miR-206 feedback pathway that oppositely affects protein translation in normal cells and cancer cells. (PMID:21518959)
• The specific co-regulation of miR-133b and miR-206 with the Il17a/f locus shown in mice also extended to human Th17 cells. (PMID:21637854)
• Results describe the profile of miR-1, miR-133a, miR-133b and miR-206 in human muscle cells isolated during different stages of fetal development. (PMID:21645416)
• aberrantly expressed miRNA-206 may be associated with the development of ERalpha-positive endometrioid adenocarcinoma (EEC). (PMID:21983130)
• Down-regulation of MiR-206 is associated with laryngeal cancer. (PMID:22110210)
• Aberrant expression and functional significance ofthe miR-1/miR-133a and miR-206/miR-133b clusters in human cancers. (PMID:22308266)
• Downregulation of miR-1, -206 and -29 stabilizes the expression of PAX3 and CCND2 in both embryonal and alveolar rhabdomyosarcoma. (PMID:22330340)
• MiR-206 regulates Otx2 expression in glioma and neuroblastoma cell lines. (PMID:22508046)
• Data indicate that myomiR-206 modulates Hmgb3 expression during myogenesis. (PMID:22912879)
• This study demonstrated a novel miRNA-dependent regulation of BDNF in alzheimer disease. (PMID:22926857)
• Data indicate that miR-206 overexpression increases apoptosis in pulmonary artery smooth muscle cell. (PMID:23071643)
• miR-206 could suppress gastric carcinoma cell proliferation at least partially through targeting cyclinD2 expression. (PMID:23348698)
• tumour suppressive role of miR-206 in the progression of breast cancer, at least partly via up-regulation of the expression of cyclin D2 (PMID:23466356)
• The miR-206 inhibit lipogenesis by suppressing the expression and activity of LXRalpha in hepatocytes. (PMID:23499676)
• Decreased miR-206 was significantly associated with advanced clinical breast cancer stage and lymph node metastasis. (PMID:23696595)
• Downregulation of miR-206 was significantly correlated with tumor progression and may be a potent prognostic marker of gastric cancer. (PMID:23751352)
• Decreased miR-206 expression was associated with advanced clinical stage and metastasis in osteosarcoma. (PMID:23886177)
• Loss of NRF2 decreased the expression of the redox-sensitive histone deacetylase, HDAC4, resulting in increased expression of miR-1 and miR-206. (PMID:23921124)
• expression of miR-206 and its target gene, fn 1, may contribute to the progression of bronchopulmonary dysplasia (PMID:24040336)
• a novel activity for miR-206 in skeletal muscle differentiation. Cyclin D1 is identified as a major target that further strengthens the tumor suppressor function proposed for miR-206. (PMID:24107628)
• the attenuated expression of miR-206, and the augmented frequency of Th17 cells in dermatomyositis patients. (PMID:24288551)
• These observations support hsa-miR-206 as a tumor suppressor in melanoma and identify Cyclin C, Cyclin D1, and CDK4 as miR-206 targets. (PMID:24289491)
• MiR-206 could be a valuable marker of astrocytoma progression. (PMID:24390803)
• We found that the levels of muscle-specific microRNAs, especially miR-206, in the serum of Duchenne muscular dystrophy were 2- to 4-fold higher than in the controls (PMID:24460924)
• miR-206 is a promising candidate biomarker for amyotrophic lateral sclerosis (PMID:24586506)
• findings provide initial evidence of the gene-to-gene interaction of MIR206 and BDNF in regards to the risk for BD-I as well as treatment response to mood stabilizers (PMID:24767015)
• Taken together, our results uggest that miR-206 is a potential regulator of apoptosis, the cell cycle and migration in HepG2 cells and that it has the potential for use in the targeted therapy of HCC and is a novel tumor suppressor (PMID:24919811)
• Findings suggest that the EVI-1 rs6774494 G > A single nucleotide polymorphism targeted by miRNA-206/133b may contribute to the pathogenesis of breast cancer. (PMID:24935473)
• the aberrant expression of miR-133b and miR-206 may be implicated in tumorigenesis and tumor progression of osteosarcoma (PMID:25120799)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	mir206-2	ENSDARG00000081661
danio_rerio	mir206-1	ENSDARG00000082396
mus_musculus	Mir206	ENSMUSG00000065559
rattus_norvegicus	Mir206	ENSRNOG00000035498
drosophila_melanogaster	mir-1	FBGN0262455
caenorhabditis_elegans	cel-mir-1	WBGENE00003260

Paralogs (2): MIR1-1 (ENSG00000199017), MIR1-2 (ENSG00000284453)

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.